- Home
- BLND vs AUTL Comparison
BLND vs AUTL Comparison
Compare BLND & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLND | AUTL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | 407.2M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BLND | AUTL |
|---|---|---|
| Price | $1.56 | $1.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.13 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 2.8M | 1.3M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,585,000.00 | $10,120,000.00 |
| Revenue This Year | $12.62 | $80.32 |
| Revenue Next Year | $14.00 | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $1.33 | $1.15 |
| 52 Week High | $4.49 | $2.70 |
Technical Indicators
Market Signals| Indicator | BLND | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 61.11 |
| Support Level | $1.56 | $1.22 |
| Resistance Level | $1.69 | $1.69 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 60.66 | 84.75 |
Price Performance
Historical ComparisonAbout BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.